Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Low-dose Radiotherapy, Tislelizumab, Combined With Albumin-bound Paclitaxel and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NeoRTPC02): an Open Label, Single-arm, Phase II Clinical Trial

NCT05343325 is registered in ClinicalTrials.gov with Fifth Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT05343325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05343325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Low-dose Radiotherapy, Tislelizumab, Combined With Albumin-bound Paclitaxel and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NeoRTPC02): an Open Label, Single-arm, Phase II Clinical Trial
Lead sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 9, 2022
Completion date
March 31, 2027
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, neoadjuvant treatment